Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Ríos, José; Bouattour, Mohamed; El Kassas, Mohamed; Leal, Cassia Regina Guedes; Mocan, Tudor; Nault, Jean-Charles; Alves, Rogerio Camargo Pinheiro; Reeves, Helen L; da Fonseca, Leonardo; García-Juárez, Ignacio; Pinato, David J; Varela, María; Alqahtani, Saleh A; Alvares-da-Silva, Mario Reis; Bandi, Juan C; ... (2022). Outcome of liver cancer patients with SARS-CoV-2 infection. Liver international, 42(8), pp. 1891-1901. Wiley 10.1111/liv.15320
|
Text
Liver_International_-_2022_-_Mu_oz_Mart_nez_-_Outcome_of_liver_cancer_patients_with_SARS_CoV_2_infection.pdf - Accepted Version Available under License Publisher holds Copyright. Download (432kB) | Preview |
BACKGROUND & AIMS
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.
METHODS
Multicenter retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February-December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
RESULTS
Two-hundred-fifty patients from 38 centers were included, 218 with hepatocellular carcinoma (HCC), 32 with intrahepatic cholangiocarcinoma (iCCA). Median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts, respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 [IQR:1.84-11.24] months, 100 (40%) patients have died,48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage [6.10%(95%CI 2.24-12.74), 11.76%(95%CI 4.73-22.30), 20.69%(95%CI 11.35-31.96), and 34.52%(95%CI 17.03-52.78) for BCLC 0/A, B, C and D respectively; p=0.0017]. The Hazard Ratio was 1.45 (95%CI 0.49-4.31; p=0.5032) in BCLC-B vs 0/A, and 3.13 (95%CI 1.29-7.62; p=0.0118) in BCLC-C vs 0/A in the Competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, 12 deaths related to SARS-CoV-2 infection.
CONCLUSIONS
This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery |
UniBE Contributor: |
Lachenmayer, Anja |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1478-3231 |
Publisher: |
Wiley |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
25 May 2022 12:08 |
Last Modified: |
26 May 2023 00:25 |
Publisher DOI: |
10.1111/liv.15320 |
PubMed ID: |
35608939 |
Uncontrolled Keywords: |
COVID-19 Hepatocellular carcinoma Liver cancer mortality |
BORIS DOI: |
10.48350/170248 |
URI: |
https://boris.unibe.ch/id/eprint/170248 |
Actions (login required)
 |
Edit item |